In the asthma model (OVA), the GPR43 expression was reduced compared with the control group, while the treatment of OVA+Alanylglutamine and OVA+NaB markedly enhanced the expression of GPR43 (Figure 8). The gene discussed is FFAR2; the disease is asthma.